Author pages are created from data sourced from our academic publisher partnerships and public sources.
Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis.
- P. Anagnostis, V. Athyros, K. Tziomalos, A. Karagiannis, D. Mikhailidis
- The Journal of clinical endocrinology and…
- 1 August 2009
CONTEXT The metabolic syndrome (MetS) is a cluster of metabolic abnormalities that increase the risk for type 2 diabetes mellitus and vascular disease. The common characteristics of MetS and… Expand
Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease…
- V. Athyros, K. Tziomalos, T. Gossios, Theodora Griva, for the Greace Study Collaborative Group
- The Lancet
- 4 December 2010
BACKGROUND Long-term statin treatment reduces the frequency of cardiovascular events, but safety and efficacy in patients with abnormal liver tests is unclear. We assessed whether statin therapy is… Expand
Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.
- V. Athyros, A. Papageorgiou, V. V. Athyrou, D. S. Demitriadis, A. Kontopoulos
- Diabetes care
- 1 July 2002
OBJECTIVE This study evaluated the effect of a atorvastatin-fenofibrate combination on lipid profile, in comparison to each drug alone, in patients with type 2 diabetes and combined hyperlipidemia… Expand
Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention
- V. Athyros, A. Papageorgiou, +5 authors A. Kontopoulos
- Current medical research and opinion
- 1 January 2002
Summary Background: Atorvastatin is very effective in reducing plasma low-density lipoprotein cholesterol (LDL-C) levels. However, there is no long-term survival study that evaluated this statin.… Expand
Pheochromocytoma: an update on genetics and management.
- A. Karagiannis, D. Mikhailidis, V. Athyros, F. Harsoulis
- Endocrine-related cancer
- 1 December 2007
Pheochromocytomas (PHEOs) are rare neoplasms that produce catecholamines and usually arise from the adrenal medulla and are considered to be an adrenal paraganglioma (PGL). Closely related tumors of… Expand
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study
- V. Athyros, D. Mikhailidis, +7 authors M. Elisaf
- Current medical research and opinion
- 4 April 2006
ABSTRACT Background: Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome (MetS). There is no established treatment for NAFLD. Aim: To evaluate a… Expand
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses.
- D. Mikhailidis, M. Elisaf, +15 authors E. Liberopoulos
- Current vascular pharmacology
- 31 August 2011
Aim of the present Consensus Statement is to provide a comprehensive and up to-date document on the pathophysiology, atherogenicity and clinical significance of low density liproproteins (LDL)… Expand
Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
- V. Athyros, K. Tziomalos, N. Katsiki, M. Doumas, A. Karagiannis, D. Mikhailidis
- World journal of gastroenterology
- 14 June 2015
Non-alcoholic fatty liver disease (NAFLD) is considered to be an independent cardiovascular disease (CVD) risk factor. However, simple steatosis has a benign clinical course without excess mortality.… Expand
Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities?
- P. Anagnostis, A. Karagiannis, A. Kakafika, K. Tziomalos, V. Athyros, D. Mikhailidis
- Osteoporosis International
- 1 February 2009
Osteoporosis and atherosclerosis, two multifactorial and degenerative entities, are major public health problems. These diseases accompany the aging process and share common risk factors.… Expand
Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study.
- V. Athyros, E. Ganotakis, +7 authors M. Elisaf
- Hellenic journal of cardiology : HJC = Hellenike…
- 1 November 2005
INTRODUCTION There are no data concerning the degree of awareness, treatment and control of the metabolic syndrome (MetS) and its components or associated vascular risk in the general population. … Expand